Share

Contacts

  • Dignitana AB
    Traktorgränden 3, SE - 226 60 Lund, Sweden
    +46 46 163090
    http://www.dignitana.com
  • Quotes

    We hope this expanded FDA clearance will be welcome news for thousands of Americans diagnosed with solid tumors each year.
    Bill Cronin, CEO Dignitana Inc
    The new decision by the FDA means that our potential market in the US is more than tripled.
    Johan Ericsson
    “The CHILL Registry is an incredible platform that will allow us to track progress and connect with physicians around the world to ensure that we can continue to deliver the most effective scalp cooling treatments available.”
    Johan Ericsson, CEO Dignitana AB
    “Dignitana is keen to align with support groups in the area to facilitate awareness and access to DigniCap treatments”
    William Cronin, Chief Executive Officer of Dignitana, Inc
    Mario Lacouture, MD, Director of the Oncodermatology Program at Memorial Sloan Kettering
    Scalp cooling is clinically proven and can be an important tool for many women in treatment for breast cancer.
    Mario Lacouture, MD, Director of the Oncodermatology Program at Memorial Sloan Kettering
    As a world leader in comprehensive cancer care, we are proud to be able to offer our patients across the New York metro area this new FDA-cleared advancement that addresses one of the most distressing and most visible side effects of chemotherapy.
    William Cronin, Chief Executive Officer of Dignitana, Inc.
    We have just passed the one-year anniversary of clearance by the FDA for DigniCap® in the U.S., and we are proud to add Memorial Sloan Kettering, one of the top comprehensive cancer centers in the U.S., to the growing number of facilities that are providing this treatment option to patients on a large scale.
    William Cronin, Chief Executive Officer of Dignitana, Inc.
    Bringing the DigniCap® system to MSK is an important milestone for Dignitana.
    We are pleased with the consistent strong growth we are experiencing in the U.S. since FDA clearance nine months ago. The DigniCap system is being included as an integral part of the treatments offered by national leaders in comprehensive breast health services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have been ordered for installation by US customers.
    Jan Richardsson, Chief Executive Officer of Dignitana
    We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests. From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.
    Jan Richardsson, Chief Executive Officer of Dignitana
    This FDA clearance means that finally, breast cancer patients in the U.S. will have access to a convenient, safe and scientifically proven option for reducing chemotherapy-induced hair loss.
    Jan Richardsson, CEO Dignitana AB
    Working with the professionals at our clinical trial sites has given us a significant head start in learning how best to provide the DigniCap® scalp cooling system here in the U.S.
    Bill Cronin, COO Dignitana Inc.
    The time is right to introduce DigniCap® at SABCS to physicians who are eager to provide their patients with an alternative to one of the most widely feared side effects of chemotherapy.
    Jan Richardsson, CEO Dignitana AB
    “We feel honored to be nominated and ranked as one of the fastest growing technology companies by Deloitte. We’ve grown during the ranking’s period, and we have fantastic journey in front of us with United States Food and Drug Administration approval pending.”
    Jan Richardsson, CEO, Dignitana AB
    To have recruited all patients is a milestone for our company and a major step forward in our PMA process.
    Erika Bågeman, Clinical Affairs Manager, Dignitana AB
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe